title: Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
abstract: OBJECTIVE
  Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 34 patients aged less than 75 years old with locally advanced stage III NSCLC were enrolled. The patients received intravenous infusions of cisplatin (80 mg/m(2); day 1) and docetaxel (20 mg/m(2); days 1, 8, 15), followed by a week's drug-free interval. Standard concurrent thoracic radiotherapy was given for 6 weeks (2 Gy per fraction; total dose, 60 Gy).
  
  
  RESULTS
  Over Grade 3 neutropenia, esophagitis and pulmonary toxicities were observed in 23.5, 17.6 and 11.8% of the cases, respectively. One complete response and 20 partial responses were obtained, with an objective response rate of 61.8%. The median survival time was 26.4 months (95% CI 16.9--not reached) and the 1- and 3-year survival rates were 76.5 and 41.2%, respectively.
  
  
  CONCLUSIONS
  Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Nakamura
authors.forename: Tomonobu
authors.initials: T
authors.lastname: Koizumi
authors.forename: Munehara
authors.initials: M
authors.lastname: Hayasaka
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuo
authors.forename: Kenji
authors.initials: K
authors.lastname: Tsushima
authors.forename: Keishi
authors.initials: K
authors.lastname: Kubo
authors.forename: Kotaro
authors.initials: K
authors.lastname: Gomi
authors.forename: Naoto
authors.initials: N
authors.lastname: Shikama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011829:Radiation Dosage; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013909:Thorax
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin